Skip to main content
. Author manuscript; available in PMC: 2021 Aug 27.
Published in final edited form as: Anticancer Drugs. 2012 Feb;23(2):161–172. doi: 10.1097/CAD.0b013e32834dc279

Figure 1: Vandetanib treatment significantly reduced outgrowth of Lewis Lung Carcinoma and B16.F10 melanoma.

Figure 1:

A+B: LLC and B16.F10-bearing mice were treated i.p. daily with 80 mg/kg of the VEGFR2 inhibitor vandetanib in 5% arabic gum or with vehicle alone. Treatment was started when tumors appeared palpable and continued for 10 (LLC vehicle and vandetanib group), 9 (B16 vehicle group) or 12 (B16 vandetanib group) days. In the LLC model, treatment was omitted at the 3rd and 8th day after start of therapy. Graph represents tumor growth curves of each mouse (tumor) separately. The average tumor volumes in vandetanib-treated mice at day 10 (LLC) or day 9 (B16.F10) after start of treatment were significantly smaller than in vehicle-treated mice (Mann-Whitney U test; p<0.05).